| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Boundless Bio, Inc. have bought $0 and sold $0 worth of Boundless Bio, Inc. stock.
On average, over the past 5 years, insiders at Boundless Bio, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 172,413 shares for transaction amount of $2.5M was made by 5AM Partners III, LLC (former 10% owner) on 2017‑04‑24.
| 2019-11-08 | Sale | Patterson Matthew R | Chief Executive Officer | 14,426 1.5528% | $30.00 | $432,780 | ||
| 2019-08-12 | Sale | Patterson Matthew R | Chief Executive Officer | 20,000 2.4429% | $34.04 | $680,835 | ||
| 2019-02-25 | Sale | Patterson Matthew R | Chief Executive Officer | 4,000 0.4306% | $30.00 | $120,000 | ||
| 2018-10-01 | Sale | Patterson Matthew R | Chief Executive Officer | 21,000 2.8754% | $38.16 | $801,372 | ||
| 2018-09-18 | Sale | Patterson Matthew R | Chief Executive Officer | 12,952 1.8589% | $40.00 | $518,080 | ||
| 2018-07-05 | Sale | Patterson Matthew R | Chief Executive Officer | 23,147 3.3256% | $40.04 | $926,852 | ||
| 2018-07-03 | Sale | Patterson Matthew R | Chief Executive Officer | 26,901 3.866% | $40.05 | $1.08M | ||
| 2018-07-02 | Sale | Patterson Matthew R | Chief Executive Officer | 21,000 2.8903% | $38.36 | $805,524 | ||
| 2018-05-21 | Sale | Patterson Matthew R | President & CEO | 20,300 2.779% | $38.15 | $774,498 | ||
| 2018-04-02 | Sale | Patterson Matthew R | President & CEO | 700 0.0754% | $30.01 | $21,009 | ||
| 2018-03-12 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 18,003 2.26% | $34.99 | $629,859 | ||
| 2018-03-09 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 80,000 10.226% | $35.63 | $2.85M | ||
| 2018-03-08 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 58,428 7.1405% | $34.06 | $1.99M | ||
| 2018-03-06 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 11,372 1.3477% | $33.03 | $375,617 | ||
| 2018-03-05 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 200 0.0259% | $36.06 | $7,212 | ||
| 2018-03-02 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 421,638 53.2032% | $35.17 | $14.83M | ||
| 2017-10-02 | Sale | Patterson Matthew R | President & CEO | 25,000 2.5047% | $27.92 | $698,070 | ||
| 2017-09-29 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 672,000 68.116% | $28.25 | $18.98M | ||
| 2017-09-18 | Sale | Patterson Matthew R | President & CEO | 8,458 0.7607% | $25.07 | $212,010 | ||
| 2017-09-15 | Sale | Patterson Matthew R | President & CEO | 1,542 0.1383% | $25.00 | $38,551 |
| Increased Positions | 16 | +41.03% | 1M | +12.9% |
| Decreased Positions | 14 | -35.9% | 2M | -21.63% |
| New Positions | 6 | New | 239,990 | New |
| Sold Out Positions | 5 | Sold Out | 2M | Sold Out |
| Total Postitions | 41 | +5.13% | 9M | -8.73% |